Stephens Investment Management Group LLC Sells 157,389 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Stephens Investment Management Group LLC sold 157,389 shares of Supernus Pharmaceuticals, reducing its ownership by 9.1% and now holds 1,581,093 shares valued at approximately $49.8 million.
• Analyst ratings for Supernus Pharmaceuticals have shifted recently, with Piper Sandler upgrading the stock from "neutral" to "overweight" and raising the price target from $40 to $65.
• Insiders, including CEO Jack A. Khattar and CFO Timothy C. Dec, have sold significant shares recently, indicating potential insider sentiment about the company's stock performance.

Stephens Investment Management Group LLC lowered its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 9.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,581,093 shares of the specialty pharmaceutical company's stock after selling 157,389 shares during the period. Stephens Investment Management Group LLC owned 2.82% of Supernus Pharmaceuticals worth $49,836,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of SUPN. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Supernus Pharmaceuticals during the second quarter worth approximately $1,536,000. Mutual of America Capital Management LLC increased its holdings in Supernus Pharmaceuticals by 5.3% during the 2nd quarter. Mutual of America Capital Management LLC now owns 212,691 shares of the specialty pharmaceutical company's stock worth $6,704,000 after purchasing an additional 10,726 shares in the last quarter. Yousif Capital Management LLC increased its holdings in Supernus Pharmaceuticals by 1.5% during the 2nd quarter. Yousif Capital Management LLC now owns 21,032 shares of the specialty pharmaceutical company's stock worth $663,000 after purchasing an additional 305 shares in the last quarter. Meritage Portfolio Management increased its holdings in Supernus Pharmaceuticals by 2.7% during the 2nd quarter. Meritage Portfolio Management now owns 60,398 shares of the specialty pharmaceutical company's stock worth $1,904,000 after purchasing an additional 1,595 shares in the last quarter. Finally, CWM LLC increased its holdings in Supernus Pharmaceuticals by 92.4% during the 2nd quarter. CWM LLC now owns 3,080 shares of the specialty pharmaceutical company's stock worth $97,000 after purchasing an additional 1,479 shares in the last quarter.

Analyst Ratings Changes

A number of analysts have commented on SUPN shares. Wall Street Zen lowered Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, October 3rd. Weiss Ratings reissued a "hold (c)" rating on shares of Supernus Pharmaceuticals in a report on Wednesday, October 8th. Piper Sandler raised Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $40.00 to $65.00 in a report on Thursday, October 9th. Zacks Research raised Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, September 17th. Finally, Cantor Fitzgerald boosted their price objective on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an "overweight" rating in a report on Tuesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $64.00.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, CFO Timothy C. Dec sold 11,780 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $44.49, for a total transaction of $524,092.20. Following the sale, the chief financial officer owned 1,246 shares in the company, valued at $55,434.54. This represents a 90.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jack A. Khattar sold 59,900 shares of the stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $50.57, for a total value of $3,029,143.00. Following the sale, the chief executive officer owned 1,206,578 shares in the company, valued at approximately $61,016,649.46. This represents a 4.73% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 362,741 shares of company stock worth $16,390,592 over the last 90 days. Corporate insiders own 8.80% of the company's stock.

Supernus Pharmaceuticals Trading Down 1.8%

Shares of NASDAQ SUPN opened at $50.67 on Wednesday. The stock has a fifty day simple moving average of $46.31 and a two-hundred day simple moving average of $37.54. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $52.15. The firm has a market cap of $2.84 billion, a price-to-earnings ratio of 44.06 and a beta of 0.78.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.